# KEYNOTE-B15/EV-304 Phase 3 Trial Shows EV+Pembro Cuts Bladder Cancer Recurrence Risk by 47% vs Chemotherapy

> clinical trial · REPORTED · 2026-07-22

The open-label KEYNOTE-B15/EV-304 phase 3 trial published in NEJM on July 22, 2026 found that perioperative enfortumab vedotin plus pembrolizumab achieved a 79.4% two-year event-free survival versus 66.2% with standard chemotherapy in muscle-invasive bladder cancer, with a hazard ratio of 0.53. Pathologic complete response was nearly double at 55.8% versus 32.5% with cisplatin-gemcitabine.

About Pfizer / Astellas (enfortumab vedotin + pembrolizumab): Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, combined with pembrolizumab (anti-PD-1) as a perioperative immunotherapy regimen for muscle-invasive bladder cancer patients.

- Company: Pfizer / Astellas (enfortumab vedotin + pembrolizumab)
- Sector: oncology
- Primary source: https://globalrph.com/2026/07/top-medical-news-topics-clinicians-should-know-this-week-july-20-26-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.